As a $677m evergreen fund, the proceeds from any exits will now be reinvested, Merck said.
Merck KGaA, a Germany-based healthcare and technology group, has increased its commitment to corporate venture capital with a further €600m ($677m) to invest over the next five years.
As an evergreen fund, the proceeds from any exits will now be reinvested, Merck said.
Merck’s CVC unit, M Ventures, had previously been allocated €400m and has invested in more than 80 portfolio companies, including Artios Pharma, DNA Script, Memryx, Mosa Meat, Padlock Therapeutics, Progyny Inc, and SeeQC.
“Over the past decade,…
